Frequency of brain metastases and outcomes in patients with HER2-, KRAS-, and EGFR-mutant lung cancers.

被引：1
|
作者：
Kris, Mark G. [1 ]
Offin, Michael David [1 ]
Feldman, Daniel L. [1 ]
Ni, Ai [1 ]
Lai, Wei-Chu Victoria [1 ]
Arbour, Kathryn Cecilia [1 ]
Daras, Mariza [1 ]
Pentsova, Elena [1 ]
DeAngelis, Lisa Marie [1 ]
Beal, Kathryn [1 ]
Young, Robert J. [1 ]
Jordan, Emmet [1 ]
Arcila, Maria E. [1 ]
Jones, David Randolph [1 ]
Isbell, James M. [1 ]
Riely, Gregory J. [1 ]
Drilon, Alexander E. [1 ]
Yu, Helena Alexandra [1 ]
Li, Bob T. [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.9081
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9081
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Frequency and outcomes of brain metastases in patients with HER2-mutant lung cancers
    Offin, Michael
    Feldman, Daniel
    Ni, Ai
    Myers, Mackenzie L.
    Lai, W. Victoria
    Pentsova, Elena
    Boire, Adrienne
    Daras, Mariza
    Jordan, Emmet J.
    Solit, David B.
    Arcila, Maria E.
    Jones, David R.
    Isbell, James M.
    Beal, Kathryn
    Young, Robert J.
    Rudin, Charles M.
    Riely, Gregory J.
    Drilon, Alexander
    Tabar, Viviane
    DeAngelis, Lisa M.
    Yu, Helena A.
    Kris, Mark G.
    Li, Bob T.
    [J]. CANCER, 2019, 125 (24) : 4380 - 4387
  • [2] Comparable clinical outcomes in patients with HER2-mutant and EGFR-mutant lung adenocarcinomas
    Gow, Chien-Hung
    Chang, Hou-Tai
    Lim, Chor-Kuan
    Liu, Chao-Yu
    Chen, Jin-Shing
    Shih, Jin-Yuan
    [J]. GENES CHROMOSOMES & CANCER, 2017, 56 (05): : 373 - 381
  • [3] A phase 1 study of osimertinib and bevacizumab as initial treatment for patients with EGFR-mutant lung cancers.
    Yu, Helena Alexandra
    Hayes, Sara A.
    Young, Robert J.
    Ni, Ai
    Rodriguez, Christopher
    Makhnin, Alex
    Riely, Gregory J.
    Kris, Mark G.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [4] A phase 1/2 study of osimertinib and bevacizumab as initial treatment for patients with metastatic EGFR-mutant lung cancers.
    Yu, Helena Alexandra
    Kim, Rachel
    Makhnin, Alex
    Ahn, Linda Su Hyun
    Ni, Ai
    Hayes, Sara A.
    Young, Robert J.
    Riely, Gregory J.
    Kris, Mark G.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [5] Outcomes Among Patients with EGFR-Mutant Metastatic NSCLC with and without Brain Metastases
    Nadler, E.
    Pavilack, M.
    Espirito, J.
    Baidoo, B.
    Fernandes, A.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S383 - S383
  • [6] Clinical outcomes of leptomeningeal metastases in EGFR-mutant lung adenocarcinoma
    Shen, C-I.
    Chiu, C-H.
    [J]. ANNALS OF ONCOLOGY, 2019, 30
  • [7] Upfront whole brain radiotherapy for multiple brain metastases in patients with EGFR-mutant lung adenocarcinoma
    Li, Changhui
    Guo, Jindong
    Zhao, Lei
    Hu, Fang
    Nie, Wei
    Wang, Huimin
    Zheng, Xiaoxuan
    Shen, Yinchen
    Gu, Ping
    Zhang, Yujun
    Zhang, Xueyan
    [J]. CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 3433 - 3443
  • [8] Upfront whole brain radiotherapy for multiple brain metastases in patients with EGFR-mutant lung adenocarcinoma
    Li, C.
    Guo, J.
    Zhao, L.
    Hu, F.
    Nie, W.
    Wang, H.
    Zheng, X.
    Shen, Y.
    Gu, P.
    Zhang, Y.
    Zhang, X.
    [J]. ANNALS OF ONCOLOGY, 2019, 30
  • [9] Brain metastases in patients with EGFR-mutant non-small-cell lung cancer
    Rosell, Rafael
    Karachaliou, Niki
    [J]. LANCET RESPIRATORY MEDICINE, 2017, 5 (09): : 669 - 671
  • [10] ERLOTINIB VERSUS RADIATION THERAPY FOR BRAIN METASTASES IN PATIENTS WITH EGFR-MUTANT LUNG ADENOCARCINOMA
    Gerber, Naamit K.
    Yamada, Yoshiya
    Shi, Weiji
    Zhang, Zhigang
    Riely, Gregory
    Beal, Kathryn
    Yu, Helena A.
    Chan, Timothy A.
    Rimner, Andreas
    Wu, Abraham J.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S902 - S902
12345